Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alpha-1 antitrypsin - Kamada

Drug Profile

Alpha-1 antitrypsin - Kamada

Alternative Names: A1AT; A1PI; AAT; AAT-IH; AAT-IV; Alpha-1 Antitrypsin; Alpha-1-Antiproteinase; alpha-1-proteinase inhibitor; ALPHA.1-PROTEINASE INHIBITOR HUMAN; Aralast; G1-AAT IV; Glassia; Infinia; Inhaled-AAT; IV AAT; Kamada-API; Prolastin-C

Latest Information Update: 18 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kamada
  • Developer Kamada; Shire
  • Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Immunomodulators; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Bronchiectasis; Alpha 1-antitrypsin deficiency; Cystic fibrosis; Type 1 diabetes mellitus
  • New Molecular Entity No

Highest Development Phases

  • Marketed Alpha 1-antitrypsin deficiency
  • Phase II/III Graft-versus-host disease; Type 1 diabetes mellitus
  • Phase II Bronchiectasis; Cystic fibrosis; Lung transplant rejection

Most Recent Events

  • 10 Jul 2018 Kamada receives positive scientific advice from Committee for Medicinal Products for Human Use (CHMP) for its pivotal phase III trial for alpha-1 antitrypsin deficiency
  • 30 May 2018 Kamada terminates a phase II/III trial due to business reasons in Graft-versus-host disease (Adjunctive treatment) in USA (IV) (NCT02956122)
  • 23 Apr 2018 Kamada intends to initiate a phase III trial in Alpha-1 antitrypsin deficiency in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top